Gaziano, 2010)
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide acts on GLP-1 receptors alone and tirzepatide targets both GIP and GLP-1 receptors
These include orlistat, phentermine-topiramate (FDA-approved only), naltrexone-bupropion, liraglutide, setmelanotide, semaglutide, and tirzepatide [9, 10]
Previous research had suggested some benefit for kidney transplant recipients with a history of type 2 diabetes who took the medications, originally designed to treat diabetes, at some point after their transplant and then experienced slower declines in kidney function than those who did not
Two doses of 10mg in close succession would deliver 20mg to your system, well above the maximum approved dose of 15mg, and would significantly increase side effect risk